ConductScience.org, home

Paper40323342

Differentiating IL-23 Inhibitors in Crohn's Disease.

Nardone OM and 4 others. Drugs, 2025. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Differentiating IL-23 Inhibitors in Crohn's Disease. Papers, record 40323342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40323342

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Differentiating IL-23 Inhibitors in Crohn's Disease.
PubMed
Journal
Drugs
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
1.73, provisional
iCite
Revised in PubMed
2026-11-03
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nardone OMOlga Mariahttps://orcid.org/0000-0002-9554-4785
2Vuyyuru SKSudheer K
3Yuan YYuhong
4Hanzel JJurij
5Jairath VVipulhttps://orcid.org/0000-0002-1092-0033

Source PubMed

Download CSV of authors

Topics3

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Crohn DiseaseMajor topic
Interleukin-23Major topic
Humans

References55

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129909019Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.Gastroenterology2018https://conductscience.org/library/papers/29909019PubMed
235839335Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.J Dermatolog Treat2022https://conductscience.org/library/papers/35839335PubMed
330032288Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.J Crohns Colitis2018https://conductscience.org/library/papers/30032288PubMed
438104569Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.Lancet Gastroenterol Hepatol2024https://conductscience.org/library/papers/38104569PubMed
527189910Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.Clin Gastroenterol Hepatol2016https://conductscience.org/library/papers/27189910PubMed
635644155
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet2022https://conductscience.org/library/papers/35644155PubMed
739461795IL-23 inhibition for chronic inflammatory disease.Lancet2024https://conductscience.org/library/papers/39461795PubMed
839018531Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.N Engl J Med2024https://conductscience.org/library/papers/39018531PubMed
92504877Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.J Exp Med1989https://conductscience.org/library/papers/2504877PubMed
1038215029Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study.Inflamm Bowel Dis2024https://conductscience.org/library/papers/38215029PubMed
1135644154Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.Lancet2022https://conductscience.org/library/papers/35644154PubMed
1216267322Natalizumab induction and maintenance therapy for Crohn's disease.N Engl J Med2005https://conductscience.org/library/papers/16267322PubMed
1334652810Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.Br J Dermatol2022https://conductscience.org/library/papers/34652810PubMed
1433127595Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts.Clin Gastroenterol Hepatol2021https://conductscience.org/library/papers/33127595PubMed
1531280967Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.Lancet2019https://conductscience.org/library/papers/31280967PubMed
1627959607Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.N Engl J Med2016https://conductscience.org/library/papers/27959607PubMed
1735691323
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Lancet2022https://conductscience.org/library/papers/35691323PubMed
1838437854Crohn's disease.Lancet2024https://conductscience.org/library/papers/38437854PubMed
1940113101Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study.Gastroenterology2025https://conductscience.org/library/papers/40113101PubMed
2030824404Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.Lancet Gastroenterol Hepatol2019https://conductscience.org/library/papers/30824404PubMed

See all 55 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42433375Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.Front Immunol2026https://conductscience.org/library/papers/42433375PubMed
42012779Interleukin-23 Inhibitors in Inflammatory Bowel Disease.BioDrugs2026https://conductscience.org/library/papers/42012779PubMed
41745409Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.J Pers Med2026https://conductscience.org/library/papers/41745409PubMed
41460707Modification of the dextran sodium sulfate model to identify agents that induce or exacerbate inflammatory bowel disease.J Immunotoxicol2026https://conductscience.org/library/papers/41460707PubMed
41339249Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.Ann Med2025https://conductscience.org/library/papers/41339249PubMed
41226868Personalizing IL-23 Inhibitor Therapy in IBD: Current Evidence and Future Directions in Therapeutic Drug Monitoring and Dose Optimization.J Clin Med2025https://conductscience.org/library/papers/41226868PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IL12B3593PubTator's text mininghttps://conductscience.org/library/genes/3593NCBI Gene
IL23A51561PubTator's text mininghttps://conductscience.org/library/genes/51561NCBI Gene
IL3727178PubTator's text mininghttps://conductscience.org/library/genes/27178NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40323342

GET https://conductscience.org/api/papers/v1/40323342/references?page=2